Academic read of the day! Crossover in oncology? A concise, open-access, 2-page paper clearly framing when it is is desirable, and when its problematic, by Alyson Haslam & Vinay Prasad MD MPH in Annals of Oncology Seminal 2018 paper and still as relevant! ➡️bit.ly/3TZCOUc

x.com/i/article/1956…

Such curves (separating dramatically so early) likely indicate selection bias: patients who come for morning CAR-T may simply be in better conditions... A classic pitfall well described by Manni Mohyuddin and Vinay Prasad MD MPH in this JAMA IM paper : jamanetwork.com/journals/jamai… 1/2

David Russler-Germain, MD/PhD Confirming my hypothesis, thanks !

x.com/i/article/1954…

Laura Loomer says she is motivated by her loyalty to Trump, but White House staffers tell Gabe Kaminsky that ‘there is widespread understanding here that she’s not guided entirely by loyalties to the president.’ thefp.com/p/white-house-…

In the DeLLphI-304 trial, patients who dropped-out early, before treatment, are seemingly missing from the PFS curves. Are the reported PFS curves accurate ? If not, this would need a formal corrigendum. Could you please clarify this Amgen 🧪🔬🧬 NEJM?

Tarlatamab, the DeLLphI-304 trial, and a Kaplan-Meier mystery. x.com/Timothee_MD/st… via Timothée Olivier, MD

Great coverage from Gabe Kaminsky and The Free Press about Laura Loomer, thank you! “A lot of us strongly suspect that Sarepta helped fuel her crusade against Vinay,” a White House official told me. Another Trump administration official said, “I don’t see how it’s possible she isn’t

Update, thanks to Giannis Mountzios 🙏 and to Amgen 🧪🔬🧬, I got this reply: "Thank you for your comment. The authors confirm that all patients randomized in DeLLphi-304 have been accounted for in the efficacy analysis according to the statistical analysis plan. In particular,

Timothée Olivier, MD Giannis Mountzios Amgen 🧪🔬🧬 Always interesting analysis Timothée Olivier, MD

Honored to host Dr. Timothée Olivier, MD as the first guest in our clinical trials in oncology webinar series. Dr. Olivier covered key topics, including control arms, post-protocol care, and more. This webinar will provide valuable insights to early-career oncologists in our region.

U.S. FDA EU Medicines Agency FDA Drug Information about DeLLphi 304 trial of #tarlatamab 👇

Recent The Wall Street Journal articles are deeply problematic, Ccongrats again Kevin Bass PhD MS for unveiling it! It feels like “When wolves are cornered, they show their teeth.” Keep the great work and leadership Dr. Marty Makary !

Just finished Malignant by Vinay Prasad MD MPH, without doubt one of the most powerful books I’ve read and a must-read for every oncologist. It sharpens how we interpret trials, exposes low-value high-cost cancer drugs, and reinforces that we must always put patients first.

Some overlapping questions See here (+ slide below) x.com/timothee_md/st…

Sounds great chadi nabhan MD, MBA, FACP! Looking forward to it! I hope the questions of censoring will be adressed! "Can I confidently say to patients that a 3-year structured exercise program may save their lives? The CHALLENGE trial" drugdevletter.com/p/can-i-confid…